Last reviewed · How we verify
PD-1 monoclonal antibody and lenvatinib — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
PD-1 monoclonal antibody and lenvatinib (PD-1 monoclonal antibody and lenvatinib) — Chen Xiaoping.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PD-1 monoclonal antibody and lenvatinib TARGET | PD-1 monoclonal antibody and lenvatinib | Chen Xiaoping | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PD-1 monoclonal antibody and lenvatinib CI watch — RSS
- PD-1 monoclonal antibody and lenvatinib CI watch — Atom
- PD-1 monoclonal antibody and lenvatinib CI watch — JSON
- PD-1 monoclonal antibody and lenvatinib alone — RSS
Cite this brief
Drug Landscape (2026). PD-1 monoclonal antibody and lenvatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/pd-1-monoclonal-antibody-and-lenvatinib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab